TFT 2F 1000 OD ALS SMA 2 TFT 2F 500 OD TFT 2F 300 OD TFT 9F OD CIDP 5 TFT 9F 906 OD
|
|
- いおり ひがき
- 5 years ago
- Views:
Transcription
1 TFT 2F AOD AOD TFT 2F AOM AOM TFT 2F OD OD TFT 9F OD OD TFT 9F OD OD TFT 9F OD MG OD TFT 9F 9 A OD OD TFT 9F OD OM TFT 9F PM1 P PM1 P Vol. 35 No S51
2 TFT 2F 1000 OD ALS SMA 2 TFT 2F 500 OD TFT 2F 300 OD TFT 9F OD CIDP 5 TFT 9F 906 OD TFT 9F 907 OM TFT 9F 909 APD2 P APM2 P Vol. 35 No S52
3 TFT 2F OD TFT 9F OD TFT 9F OD TFT 9F OD TFT 9F OM TFT 9F PD3 P PD3 P PD3 P PD3 P PD3 P PD3 P Vol. 35 No S53
4 TFT 2F AOD AOD AOD IBGC AOD C9orf72 ALS/FTLD 2 AOD AOD Facial onset sensory and motor neuronopathy oral phase dysphagia 2 AOD AOD Embolic stroke of undetermined source 塚 AOD K PLUS AOD AOD cortical tremor Vol. 35 No S54
5 2 TFT 2F AOM AOM Hoehn Yahr IV AOM AOM AOM FIM JA AOM AOM AOM JA Vol. 35 No S55
6 3 TFT 2F OD OD OD OD OD OD paroxysmal extreme pain disorder OD OD OD OD OD gachr 2 POLR3A 1 Cronkhite Canada 1 Vol. 35 No S56
7 4 TFT 9F OD OD OD OD OD OD TIA rt PA : 3D Double inversion recovery Staphylococcus haemolyticus 1 OneStroke tpa 2 OD OD OD OD OD OD EVT C 1 塚 1 DOACs DOAC PCSK9 1 Vol. 35 No S57
8 5 TFT 9F OD OD OD OD OD MOG add on 1 MOG OD OD OD OD OD Natalizumab 11 EDSS4 1 FTY MS 1 Tumefactive demyelinating lesions Vol. 35 No S58
9 6 TFT 9F 907 MG OD OD OD OD OD MuSK 1 3,4-DAP Lambert-Eaton 1 1 OD OD OD OD OD OD OD MR 9 zonisamide Quetiapine Parkinson 1 Vol. 35 No S59
10 7 TFT 9F 9 A OD OD OD OD OD neurofascin155 CIDP T facial onset sensory and motor neuronopathy 47 AL 15 OD OD OD OD OD OD OD GABAB 2 ADA 1 2 / NMDA 21 1 AMPA 1 Vol. 35 No S60
11 8 TFT 9F OD OD OD OD Pembrilizumub 78 M OM OM OM OM OM HAL 1 Vol. 35 No S61
12 TFT 9F PM1 P 01 PM1 P 02 PM1 P 03 PM1 P 04 PM1 P 05 PM1 P 06 MTPSSE 1 LSVT BIG PM1 P 07 PM1 P 08 PM1 P 09 PM1 P 10 PM1 P 11 PM1 P 12 LCIG 1 CIDP 1 1 Vol. 35 No S62
13 TFT 2F 1000 ALS SMA OD OD OD OD OD NIV ALS III 2 2 Vol. 35 No S63
14 2 TFT 2F 500 OD OD OD OD Arterial Spin Labeling ASL 1 2 Vol. 35 No S64
15 3 TFT 2F OD OD OD OD OD OD Parkinson's disease dementia PDD / L Vol. 35 No S65
16 4 TFT 9F CIDP OD OD OD OD IgG4 NF155 CIDP 1 CIDP IVIg 1 CNTN1 CIDP 1 Vol. 35 No S66
17 5 TFT 9F OD OD OD OD OD OD OD L 3 榊 3 1 aps/pt Vol. 35 No S67
18 6 TFT 9F 907 OM OM OM OM OM PD Camptocormia ADL 1 Vol. 35 No S68
19 TFT 9F 909 APD2 P APD2 P 02 DAT Parkinson APD2 P 03 APD2 P 04 ipad APD2 P 05 APD2 P 06 APM2 P 01 APM2 P 02 2 APM2 P 03 Vol. 35 No S69
20 TFT 2F OD OD OD OD OD OD Short QOL D score 1 / Vol. 35 No S70
21 4 TFT 9F OD OD OD OD OD OD SCA6, SCA31, MSA-C JA MR STN DBS directional lead 1 STN DBS Vol. 35 No S71
22 5 TFT 9F OD OD OD OD OD ATTR T Vol. 35 No S72
23 6 TFT 9F OD OD OD OD OD OD OD Ma 1 1 transcriptional intermediary factor1 TIF1 1 1 Vol. 35 No S73
24 8 TFT 9F OM OM OM JA 3 ADL 1 Vol. 35 No S74
25 TFT 9F PD3 P 01 PD3 P 02 PD3 P 03 PD3 P 04 PD3 P 05 PD3 P 06 PD3 P 07 PD3 P 08 LCIG 3 small voice 1 / PEG J PD3 P 09 PD3 P 10 PD3 P 11 PD3 P 12 PD3 P 13 PD3 P 14 PD MS 1 rtms C 1 DAT SPECT 30 1 Vol. 35 No S75
26 PD3 P 15 PD3 P PD3 P 17 PD3 P 18 PD3 P 19 PD3 P 20 PD3 P 21 PD3 P 22 programmed cell death 1 PD B R CHOP SRP 1 neurofascin155 1 CMTX PD3 P 23 PD3 P 24 PD3 P 25 PD3 P 26 PD3 P 27 PD3 P IVIG VGKC 1 Bickerstaff 7 Vol. 35 No S76
27 PD3 P 29 PD3 P 30 Epstein Barr Anti Neutrophil Cytoplasmic Antibody Garcin PD3 P 31 PD3 P 32 PD3 P 33 PD3 P 34 PD3 P 35 PD3 P 36 PD3 P 37 BONX Grip AMPA Trousseau Direct oral anticoagulant DOAC PD3 P 38 PD3 P 39 PD3 P 40 PD3 P 41 PD3 P 42 PD3 P 43 HIV MEFV Behçet 1 1 HIV AIDS Vol. 35 No S77
28 PD3 P 44 PD3 P 45 Zic4 80 CRMP 5 1 Vol. 35 No S78
OD 高頻度片頭痛および慢性片頭痛症例における眼窩上経皮的末梢神経電気刺激装置を用いた前向き観察研究 医師口演 頭痛 2018/11/23 11:10 12:10 第 3 会場 OD 起立性頭痛で発症し メニエール病が疑われ治療が奏功した37 歳男性例
AOD1-1-01 10092 ボルテゾミブを導入療法とし自家末梢血幹細胞移植が奏功した孤発性成人発症型ネマリンミオパチーの1 例 医師口演 優秀演題セッション1 2018/11/23 11:10 12:10 第 1 会場 AOD1-1-02 10074 子宮頸がんワクチン接種後神経障害の病態解明 治療法開発に向けての研究 医師口演 優秀演題セッション1 2018/11/23 11:10 12:10
More information障害者職域拡大カリキュラム研究会中間報告書構成案
3 4 5 5 7 7 9 () 9 ()23 34 1 36 47 49 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 ADL QOL 36 37 38 39 40 41 42 43 44 45 46 16 8 () 19 ( ) () 21 () 47 16
More information表1票4.qx4
iii iv v 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 22 23 10 11 24 25 26 27 10 56 28 11 29 30 12 13 14 15 16 17 18 19 2010 2111 22 23 2412 2513 14 31 17 32 18 33 19 34 20 35 21 36 24 37 25 38 2614
More informationParkinson disease : ,
1 2012 7 24 Parkinson disease :10 50 100, 65 10 200 tremor rigidity (pill rolling) Cogwheel rigidity Akinesia Bradykinesia Resting tremor in Parkinson disease Parkinson disease: camptocormia Parkinson's
More information活用ガイド (ソフトウェア編)
ii iii iv NEC Corporation 1998 v vi PA RT 1 vii PA RT 2 viii PA RT 3 PA RT 4 ix P A R T 1 2 3 1 4 5 1 1 2 1 2 3 4 6 1 2 3 4 5 7 1 6 7 8 1 9 1 10 1 2 3 4 5 6 7 8 9 10 11 11 1 12 12 1 13 1 1 14 2 3 4 5 1
More information10 12 13 16 17 26 26 31 32 33 33 35 37 38 39 42 43 44 2 15 5 15 57 17 16 4 16 4 2 JA 16 7 1 10 22 11 9 12 6 12 2 12 24 17 1 6 JA 3 4 5 16 7 1 6 ( ) ( ) 15 ( ) ( ) ( ) ( ) ( ) 16 3 35 37 1 93 223 ( ) 218
More informationuntitled
259 2012 11 21 14 17 BOAZ 1985 9 6 4 20 10 1 8 5 5 2000 8 1 1 1 3 1 1966 45 3km 7 8 9 1971 1976 2 2000 5 1 3 350 3 1 10 34 3 40 25 40 20 40 60 100 20 401 10 4 3 5 1 40 1 7 1 19 34 510 1 1 10 10 1 CSR 10
More informationi ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
More information44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
More information262014 3 1 1 6 3 2 198810 2/ 198810 2 1 3 4 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 2... 2... 4... 5... 9... 9... 10... 10... 10... 10... 13 2... 13 3... 15... 15... 15... 16 4...
More information*p145-174_Œâ‡í‡ê‡é
*p145-174_ 問 われる 09.1.16 10:34 PM ページ145 2007 200708 146 147 a s 148 a s d f g 153 a s d 158 a s d f g h j 166 a s d f 171 2009 145 *p145-174_ 問 われる 09.1.16 10:34 PM ページ146 45 2007 2008 146 *p145-174_
More information2 of 46 07.2.10 4:30 PM
1 of 46 07.2.10 4:30 PM 2 of 46 07.2.10 4:30 PM 3 of 46 07.2.10 4:30 PM 4 of 46 07.2.10 4:30 PM 5 of 46 07.2.10 4:30 PM 6 of 46 07.2.10 4:30 PM 7 of 46 07.2.10 4:30 PM 8 of 46 07.2.10 4:30 PM 9 of 46 07.2.10
More information医薬品リスク管理計画書
2.5 mg 3.75 mg 5 mg 20mg RMP 2.5 mg 3.75 mg 5 mg 20mg 87339 28 6 1.1 4 8 10 5 8 10 5 TTP 9 梗 6 TIA 11 6 1.2 11 CABG 12 12 13 13 15 2.5mg 15 2. 16 3. 16 4. 19 19 19 18 RMP 28 6 3 5 1 27 8 25 26 3 24 87339
More information終末期癌患者に対する 輸液治療の是非
3 A B NSAID D Case stories A B NSAID D Case stories A. IASP Task Force on Taxonomy WHO Collaborating Center for Palliative Cancer Care : Looking forward to cancer pain relief for all. CBC Oxford, Oxford,
More information『こみの株式会社』の実践
2003 . JA JA A JA 811 2005/8/11 1003 452 10 960 28 2005/8/11 1003 452 6 120 29 2005/8/11 2003 151 10 420 33 2005/8/11 2003 211 3 180 31 2005/8/11 2003 211 3 150 32 827 400 5 80 221 2005/6/25 900 3 300
More information15 7 26 1,276 3,800 1 16 15 1 2 3 4 2
1 15 7 26 1,276 3,800 1 16 15 1 2 3 4 2 JA 3 4 2 1 3 2001 1981 6 10% 10 30% 1 2 JA JA 2 4 JA 2 1 2 1 2 1 2 1 2 1 2 7 5 1 1 1 3 1 6 1 1 2 2 1 7 2 3 3 53 1 2000 30 8 250 53 435 20 35 3 1 8 2 4 3 2 2 232
More informationEX-word_Library_JA
JA 2 3 4 5 14 7 1 2 6 3 1 2 7 3 8 27 1 2 3 1 2 3 9 1 2 3 1 2 3 10 12 13 14 11 1 12 1 2 13 1 2 3 25 14 1 2 3 25 15 1 2 3 25 16 1 2 3 25 17 1 2 3 25 18 1 2 3 4 25 19 1 2 3 4 25 20 1 2 21 3 4 25 22 1 2 3
More information324.pdf
50 50 10 30 11 26 12 27 14 16 27 18 20 21 22 22 22 22 23 24 24 1 No.324 JA 2 85 69 20 12 81 18 12 22 93 10 31 3 50 50 30 30 50 22 27 27 10 16 14 52 10 62 15 64 25 24 50 4 25 23 27 5 10 11 25 6 11 49 10
More information5 9 22 12301430502 6 9 22 12301430505 7 9 22 14451645401 3 44
1 9 22 12301430401 2 9 22 12301430402 3 9 22 12301430403 2007 4 9 22 12301430501 43 5 9 22 12301430502 6 9 22 12301430505 7 9 22 14451645401 3 44 8 9 22 14451645402 3 9 9 22 14451645403 1 PD 10 9 22 14451645501
More information1 z q w e r t y x c q w 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 R R 32 33 34 35 36 MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR
More informationMicrosoft Word - 表紙資料2-4
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
More informationx [1] Palmer Jeffrey, B. and M. Hiiemae Karen, (propulsion). (1343-8441), 1997. 1(1): p. 15-30. [2] Saitoh, E., et al., Chewing and food consistency: effects on bolus transport and swallow initiation.
More informationiii iv v vi 21 A B A B C C 1 1 2 3 4 5 6 1 2 3 4 5 6 7 8 9 10 11 19 22 30 39 43 48 54 60 65 74 77 84 87 89 95 101 12 20 23 31 40 44 49 55 61 66 75 78 85 88 90 96 102 13 21 24 32 41 45 50 56 62 67 76 79
More information29 IL-6 IL-6 PD PD MT PTOT PD Hoehn- Yahr 5 PT OT 40 5 MT MT UPDRS FIM CASMTCL FIM UPDRS 2 3 CAS MTCL MT PT OT PD
Jpn J Rehabil Med 2011 ; : 134.142 2010 9 11 IL- Myokine Myokine 1 IL 6 10 10 IL-6 40 20 40 60 IL-6 1.39 1.01 pg ml 20 2.23 1.71 pg ml 40 2.51 2.29 pg ml 60 0.63 0.59 pg ml 0.7 0.64 pg ml 0.72 0.55 pg
More informationみさき_1
2 3 4 5 6 7 1F 2F 8 9 10 11 17 18 19 20 21 22 23 24 31 25 26 27 28 29 30 8 1 2 3 4 5 6 7 6 8 7 16 7 8 9 10 11 12 14 15 13 17 23 Vol.41 8 6 20 11 7 15 7 23 7 7 7 16 23 23 8 13 18:00 22:00 722
More informationVol..3 2010 2 10 2
1 Vol..3 2010 2 10 2 Vol..3 2010 2 10 3 Vol..3 2010 2 10 4 Vol..3 2010 2 10 5 Vol..3 2010 2 10 6 Vol..3 2010 2 10 7 Vol..3 2010 2 10 8 Vol..3 2010 2 10 9 Vol..3 2010 2 10 10 Vol..3 2010 2 10 11 Vol..3
More informationH21_report
vol.4 1 2 6 10 14 18 20 22 24 25 1 2 2172 73 3 21925 926 21125 126 4 5 6 21629 630 7 21107 108 21127 128 8 9 10 21616 617 11 211026 1027 211213 1214 12 13 14 21713 714 15 2194 95 211031 111 16 17 18 19
More information2009-9-2.indd
Q No.1441 Q No.1442 Vol.33 NO.9 (2009) 30 (614) Q No.1443 Vol.33 NO.9 (2009) 31 (615) Q No.1444 Vol.33 NO.9 (2009) 32 (616) Vol.33 NO.9 (2009) 33 (617) Vol.33 NO.9 (2009) 34 (618) Q No.1445 Vol.33 NO.9
More informationuntitled
Vol.27 1 Vol.27 2 Vol.27 3 Vol.27 4 Vol.27 5 Vol.27 6 Vol.27 7 Vol.27 8 Vol.27 9 Vol.27 10 11 Vol.27 Vol.27 12 Vol.27 13 Vol.27 14 Vol.27 15 Vol.27 16 Vol.27 17 Vol.27 2007 10 29 18 http://www.nira.or.jp/index.html
More information09030549_001.図書館31-1
vol.31 NO.1 2 3 5 6 10 12 8 1947-1954- 1950-1838-1904 1952-1996 1 913-1954 1981-1958- 1 902-1992 1972-1946- 1 940- 1 2 3 3 5 6 6 8 8 12 8 8 1 2 2 http://library.hokkai-s-u.ac.jp/cgi-bin/tosyokan/index.cgi
More informationVOL a s d f g h
VOL.20013 -- 1937 101939 1940410 1940 1 VOL.20013 2030 193810 19391034 1937 a s d f g h 1995139140161 1998348 1988236 1994577578 1998 1987151 1922 2 VOL.20013 101110 3000500 70 1929 1920 1927 70 4050 30
More information